At a glance
| Sequence | Lys–Pro–Val |
|---|---|
| Size | 3 amino acids |
| Research relationship | α-MSH-derived fragment |
| Main models | Mouse colitis; intestinal cells |
| Clinical status | Unapproved research compound |
Overview
The name KPV describes the amino-acid sequence lysine, proline and valine. Research focuses on whether this small peptide can influence inflammatory signaling while avoiding some effects of the full parent hormone. Two important distinctions are the biological model and the delivery system: a mouse receiving a specially engineered nanoparticle formulation is not equivalent to a person taking a commercially sold capsule or injection. The 2026 FDA compounding review addresses the lack of an established human product profile. This catalog includes the research without presenting it as approved gut repair.
How it works
KPV has reduced inflammatory readouts in experimental systems, including models of colitis. Some effects appear partly independent of melanocortin-1 receptor signaling, so it should not be described simply as a miniature version of every α-MSH action. Delivery to intestinal epithelial cells and macrophages is a major research issue. Nanoparticle targeting can change tissue exposure and therefore is part of the intervention, not a neutral packaging detail.
Animal colitis findings
An original study found improvement in inflammatory measures in two mouse colitis models. Experiments in animals with impaired MC1 receptor function suggested that at least part of the response did not require that receptor.
Supporting sources [1]
Why formulation changes the evidence
A later study loaded KPV into hyaluronic-acid-functionalized nanoparticles within a hydrogel. This improved targeted delivery and mouse colitis outcomes relative to comparison systems. It does not establish equivalent activity for unformulated oral KPV or injected products.
Supporting sources [2]
What has not been demonstrated
These studies do not establish remission, prevention of complications or improved quality of life in people with ulcerative colitis or Crohn’s disease. Histologic improvement in a chemically induced mouse model is a different endpoint from sustained human disease control.
The human safety gap
FDA’s 2026 assessment considered inadequate human exposure and safety information among the key concerns. A small peptide can still have uncertain immune, impurity and formulation-related risks; absence of documented reactions in a limited literature is not proof of safety.
Supporting sources [3]
What regulatory discussion means
KPV-related bulk substances were reviewed for possible compounding use in 2026. A compounding-policy discussion does not create an FDA-approved KPV drug or demonstrate that a particular commercial formulation treats inflammatory disease.
Supporting sources [3]
Reading this profile
Jurisdiction: United States — no FDA-approved KPV medicine; compounding review is a separate regulatory question.. Molecular class: Lysine–proline–valine tripeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. ↗Original research · Checked 2026-10-27
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. ↗Original research · Checked 2026-10-27
- FDA July 2026 PCAC presentations: KPV evaluation ↗Regulatory source · Checked 2026-10-27